Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Aug 17, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat
52-wk position
82.2%
-6.2% vs 52w high · +7.3% 1mo

Price (last ~year)

Elevance Health (ELV) reported second-quarter revenue of $50.47 billion and net income of $1.46 billion, marking the company's fourth consecutive earnings beat despite a 13.1% year-over-year decline in earnings. The stock, which maintains a $86.82 billion market capitalization and a 17.7 P/E ratio, saw multiple new institutional stakes acquired during the second quarter. Shares are currently priced at $400.32, reflecting a 7.3% gain over the last month.

Valuation

Market cap
$86.82B
P/E
17.7
PEG
1.417
P/B
1.934
P/S
0.432
Beta
0.692
Analyst target
$449.1

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Price movement

Last
$400.32
1-month
+7.3%
3-month
-0.1%
RSI (14)
66
vs SMA200
+14.0%
52-wk position
82.2% -6.2% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots